Anavex Life Sciences Corp (AVXL)

[Helium-3]

July 22, 2015 Anavex announced initial Phase 2a study data for Anavex 2-73, the Company’s lead investigational oral treatment for Alzheimer’s targeting sigma-1 and muscarinic receptors, which is believed to reduce protein misfolding including reduction of beta amyloid, tau and inflammation.

...Our Phase 2a clinical trial of ANAVEX 2-73 is progressing on schedule, with PART A expected to be completed by the end of the year. Additionally, we are expanding PART B, the extension period, from 26 to 52 weeks based on positive initial clinical data and at the request of study participants.

I'm assuming PART B immediately follows PART A, is this correct or is there some type of down period. Does anyone know?